Evidence map›Paper›PMID 33538845›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2021

Silymarin mitigates bile duct obstruction-induced cholemic nephropathy.

Mohammad Mehdi Ommati, Omid Farshad, Negar Azarpira, Elmira Ghazanfari, Hossein Niknahad, Reza Heidari

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Pentoxifylline mitigates cholestasis-related cholemic nephropathy.Clinical and experimental hepatology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Mohammad Mehdi Ommati *College of Life Sciences, Shanxi Agricultural University, Taigu, 030801, Shanxi, China.ORCID 0000-0003-0514-2414
Omid Farshad *Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Negar AzarpiraTransplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Elmira GhazanfariDepartment of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, P.O. Box 158371345, Roknabad, Karafarin St., Shiraz, Fars, Iran.
Hossein NiknahadPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. niknahadh@sums.ac.ir.
Reza HeidariPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. rheidari@sums.ac.ir.
Shiraz University of Medical Sciences · IRShanxi Agricultural University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bile duct obstruction or cholestasis can occur by several diseases or xenobiotics. Cholestasis and the accumulation of the bile constituents in the liver primarily damage this organ. On the other hand, extrahepatic organs are also affected by cholestasis. The kidney is the most affected tissue during cholestatic liver injury. Cholestasis-associated renal injury is known as cholemic nephropathy (CN). Several lines of evidence specify the involvement of oxidative stress and mitochondrial impairment in the pathogenesis of CN. The current study aimed to assess the role of silymarin as a potent antioxidant on CN-induced oxidative stress and mitochondrial dysfunction in the kidney. Bile duct ligated (BDL) rats were treated with silymarin (10 and 100 mg/kg, oral) for seven consecutive days. A significant increase in reactive oxygen species (ROS), lipid peroxidation, protein carbonylation, and oxidized glutathione (GSSG) levels were evident in the kidney of BDL animals. Moreover, reduced glutathione (GSH) content and total antioxidant capacity were significantly decreased in the kidney of cholestatic rats. Mitochondrial depolarization, decreased mitochondrial dehydrogenases activity, mitochondrial permeabilization, and depleted ATP stores were detected in the kidney mitochondria isolated from BDL animals. Kidney histopathological alterations, as well as serum and urine levels of renal injury biomarkers, were also significantly different in the BDL group. It was found that silymarin treatment significantly ameliorated CN-induced renal injury. The antioxidant effects of silymarin and its positive impact on mitochondrial indices seem to play a significant role in its renoprotective effects during cholestasis.

Indexed as

AnimalsAntioxidantsCholestasisDisease Models, AnimalDose-Response Relationship, DrugGlutathioneKidney DiseasesLipid PeroxidationMaleMitochondriaOxidative StressRatsRats, Sprague-DawleyReactive Oxygen SpeciesSilymarinAntioxidantsGlutathioneReactive Oxygen SpeciesSilymarinBile acidsCholestasisCirrhosisMitochondriaNephropathyOxidative stressRenal failure

Identifiers

PMID33538845
OpenAlexW3128546505

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.